Correction: Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification (Hypertension Research, (2023), 46, 1, (19-31), 10.1038/s41440-022-01036-6)

Rie Jo; Hirotaka Shibata; Isao Kurihara; Kenichi Yokota; Sakiko Kobayashi; Ayano Murai-Takeda; Yuko Mitsuishi; Takeshi Hayashi; Toshifumi Nakamura; Hiroshi Itoh

doi:10.1038/s41440-023-01167-4

Correction: Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification (Hypertension Research, (2023), 46, 1, (19-31), 10.1038/s41440-022-01036-6)

Rie Jo, Hirotaka Shibata, Isao Kurihara, Kenichi Yokota, Sakiko Kobayashi, Ayano Murai-Takeda, Yuko Mitsuishi, Takeshi Hayashi, Toshifumi Nakamura, Hiroshi Itoh

研究成果: Comment/debate › 査読

抄録

The original version of this article incorrectly stated the dosage of 6-diazo-5-oxo-L-norleucine (DON) in animal studies. The unit of DON was incorrect; it should be 3 μg/g. There are three errors regarding units of DON in “DON administration study” in Methods, “DON administration reduces tissue O-GlcNAc levels and the MR protein levels in db/db mice” in Results and the caption of Fig. 5E. The original article has been corrected.

本文言語	English
ページ（範囲）	814
ページ数	1
ジャーナル	Hypertension Research
巻	46
号	3
DOI	https://doi.org/10.1038/s41440-023-01167-4
出版ステータス	Published - 2023 3月

ASJC Scopus subject areas

内科学
生理学
循環器および心血管医学

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1038/s41440-023-01167-4

他のファイルとリンク

フィンガープリント

「Correction: Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification (Hypertension Research, (2023), 46, 1, (19-31), 10.1038/s41440-022-01036-6)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Jo, R., Shibata, H., Kurihara, I., Yokota, K., Kobayashi, S., Murai-Takeda, A., Mitsuishi, Y., Hayashi, T., Nakamura, T., & Itoh, H. (2023). Correction: Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification (Hypertension Research, (2023), 46, 1, (19-31), 10.1038/s41440-022-01036-6). Hypertension Research, 46(3), 814. https://doi.org/10.1038/s41440-023-01167-4

Jo, R, Shibata, H, Kurihara, I, Yokota, K, Kobayashi, S, Murai-Takeda, A , Mitsuishi, Y, Hayashi, T, Nakamura, T & Itoh, H 2023, 'Correction: Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification (Hypertension Research, (2023), 46, 1, (19-31), 10.1038/s41440-022-01036-6)', Hypertension Research, vol. 46, no. 3, pp. 814. https://doi.org/10.1038/s41440-023-01167-4

@article{5a65ea4fb9f04ab4beceb963ff203659,

title = "Correction: Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification (Hypertension Research, (2023), 46, 1, (19-31), 10.1038/s41440-022-01036-6)",

abstract = "The original version of this article incorrectly stated the dosage of 6-diazo-5-oxo-L-norleucine (DON) in animal studies. The unit of DON was incorrect; it should be 3 μg/g. There are three errors regarding units of DON in “DON administration study” in Methods, “DON administration reduces tissue O-GlcNAc levels and the MR protein levels in db/db mice” in Results and the caption of Fig. 5E. The original article has been corrected.",

author = "Rie Jo and Hirotaka Shibata and Isao Kurihara and Kenichi Yokota and Sakiko Kobayashi and Ayano Murai-Takeda and Yuko Mitsuishi and Takeshi Hayashi and Toshifumi Nakamura and Hiroshi Itoh",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s), under exclusive licence to The Japanese Society of Hypertension.",

year = "2023",

month = mar,

doi = "10.1038/s41440-023-01167-4",

language = "English",

volume = "46",

pages = "814",

journal = "Hypertension Research",

issn = "0916-9636",

publisher = "Springer Nature",

number = "3",

}

TY - JOUR

T1 - Correction

T2 - Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification (Hypertension Research, (2023), 46, 1, (19-31), 10.1038/s41440-022-01036-6)

AU - Jo, Rie

AU - Shibata, Hirotaka

AU - Kurihara, Isao

AU - Yokota, Kenichi

AU - Kobayashi, Sakiko

AU - Murai-Takeda, Ayano

AU - Mitsuishi, Yuko

AU - Hayashi, Takeshi

AU - Nakamura, Toshifumi

AU - Itoh, Hiroshi

PY - 2023/3

Y1 - 2023/3

N2 - The original version of this article incorrectly stated the dosage of 6-diazo-5-oxo-L-norleucine (DON) in animal studies. The unit of DON was incorrect; it should be 3 μg/g. There are three errors regarding units of DON in “DON administration study” in Methods, “DON administration reduces tissue O-GlcNAc levels and the MR protein levels in db/db mice” in Results and the caption of Fig. 5E. The original article has been corrected.

AB - The original version of this article incorrectly stated the dosage of 6-diazo-5-oxo-L-norleucine (DON) in animal studies. The unit of DON was incorrect; it should be 3 μg/g. There are three errors regarding units of DON in “DON administration study” in Methods, “DON administration reduces tissue O-GlcNAc levels and the MR protein levels in db/db mice” in Results and the caption of Fig. 5E. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85146175712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146175712&partnerID=8YFLogxK

U2 - 10.1038/s41440-023-01167-4

DO - 10.1038/s41440-023-01167-4

M3 - Comment/debate

C2 - 36635527

AN - SCOPUS:85146175712

SN - 0916-9636

VL - 46

SP - 814

JO - Hypertension Research

JF - Hypertension Research

IS - 3

ER -